Company research
Rain Oncology Inc.
CIK 1724979Updated Nov 16, 2026
Securities
Historical securities (1)
RAIN · NASDAQ · equity · closed Feb 1, 2024Name history
Rain Therapeutics Inc. · through Dec 29, 2022
RAIN price & chart
Historical security
This listing closed Feb 1, 2024. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2022 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 135,180,000Source | 147,140,000Source | 61,080,000Source |
| Property, Plant and Equipment, NetUSD | 93,000Source | 165,000Source | 99,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 61,955,000Source | 24,780,000Source | 58,863,000Source |
| Assets, CurrentUSD | 133,628,000Source | 146,146,000Source | 59,525,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,174,000Source | 5,928,000Source | 662,000Source |
| Operating Lease, Right-of-Use AssetUSD | 258,000Source | 386,000Source | 447,000Source |
| Other Assets, NoncurrentUSD | 1,201,000Source | 443,000Source | 624,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 22,144,000Source | 16,636,000Source | 3,800,000Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 37,000Source | 27,000Source | 4,000Source |
| Retained Earnings (Accumulated Deficit)USD | -165,688,000Source | -89,964,000Source | -38,570,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -166,000Source | -89,000Source | 0Source |
| Stockholders' Equity Attributable to ParentUSD | 113,036,000Source | 130,504,000Source | -37,417,000Source |
| Additional Paid in Capital, Common StockUSD | 278,853,000Source | 220,530,000Source | 1,149,000Source |
| Liabilities and EquityUSD | 135,180,000Source | 147,140,000Source | 61,080,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 21,966,000Source | 16,315,000Source | 3,419,000Source |
| Operating Lease, Liability, CurrentUSD | 164,000Source | 160,000Source | 141,000Source |
| Accounts Payable, CurrentUSD | 7,146,000Source | 6,112,000Source | 816,000Source |
| Operating Lease, Liability, NoncurrentUSD | 113,000Source | 252,000Source | 312,000Source |
| Other Liabilities, NoncurrentUSD | 65,000Source | 69,000Source | 69,000Source |
| Additional Financial Items | |||
| Deferred Tax Liabilities, NetUSD | 75,000Source | 81,000Source | 133,000Source |
| Short-term InvestmentsUSD | 68,499,000Source | 115,438,000Source | 0Source |
cash flow · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 4,855,000Source | 3,092,000Source | 865,000Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts PayableUSD | 1,034,000Source | 5,288,000Source | 555,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -63,199,000Source | -37,463,000Source | -11,231,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 47,194,000Source | -118,235,000Source | -5,191,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 8,000Source | 128,000Source | 24,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 53,180,000Source | 121,615,000Source | 69,491,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 37,175,000Source | -34,083,000Source | 53,069,000Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 4,855,000Source | 3,092,000Source | 865,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | 0Source | — |
| DepreciationUSD | 100,000Source | 100,000Source | 100,000Source |
| Gain (Loss) on InvestmentsUSD | 9,000Source | 1,000Source | — |
| General and Administrative ExpenseUSD | 15,736,000Source | 10,739,000Source | 3,591,000Source |
| Income Tax Expense (Benefit)USD | 3,000Source | 2,000Source | — |
| Investment Income, InterestUSD | 1,415,000Source | 119,000Source | 32,000Source |
| Net Income (Loss) Attributable to ParentUSD | -75,724,000Source | -51,394,000Source | -21,083,000Source |
| Nonoperating Income (Expense)USD | 1,415,000Source | 120,000Source | -2,125,000Source |
| Operating ExpensesUSD | 77,136,000Source | 51,512,000Source | 18,958,000Source |
| Proceeds from Issuance of Common StockUSD | 56,647,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | 121,000Source | 48,000Source |
income statement · annual statements
| Line item | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|
| Operating Income (Loss)USD | -77,136,000Source | -51,512,000Source | -18,958,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -75,721,000Source | -51,392,000Source | -21,083,000Source |
| Income Tax Expense (Benefit)USD | 3,000Source | 2,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -75,724,000Source | -51,394,000Source | -21,083,000Source |
| Earnings Per Share, BasicUSD per share | -2.71Source | — | — |
| Earnings Per Share, DilutedUSD per share | -2.71Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 27,985,446Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 27,985,446Source | — | — |
| Additional Financial Items | |||
| Depreciation, Depletion and Amortization, NonproductionUSD | 80,000Source | 71,000Source | 52,000Source |
| Gain (Loss) on InvestmentsUSD | 9,000Source | 1,000Source | — |
| General and Administrative ExpenseUSD | 15,736,000Source | 10,739,000Source | 3,591,000Source |
| Interest Expense, DebtUSD | — | — | 135,000Source |
| Investment Income, InterestUSD | 1,415,000Source | 119,000Source | 32,000Source |
| Nonoperating Income (Expense)USD | 1,415,000Source | 120,000Source | -2,125,000Source |
| Operating ExpensesUSD | 77,136,000Source | 51,512,000Source | 18,958,000Source |
| Research and Development ExpenseUSD | 61,400,000Source | 40,773,000Source | 15,367,000Source |